28 December 2017 – Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it remains on schedule with the development of the first LIGHT system, as per the timetable provided to shareholders on 6 March 2017, and provides the following technological update:
The Company continues to make significant advancements in the technology development and manufacture of its first LIGHT system following the successful integration and testing of the first Side Coupled Drift Tube Linac (" SCDTL") with the Radiofrequency Quadrupole (" RFQ") and proton source . Lower power testing of the individual accelerating SCDTL units have met expectations and results provide confidence that the units are now capable of accelerating a proton beam to 25MeV through the SCDTL. With much of the technological development now de-risked, the Company is on target to have a system capable of treating superficial tumours by the end of Q3 2018.
Prof. Ugo Amaldi, President of the TERA Foundation and member of Company's Medical advisory board, commented: "The most challenging part in building a new linear accelerator is the manufacturing and individual testing of the accelerating structures; their integration in a single linear accelerator is a simple process. We are very confident that SCDTLs will work properly, also because an identical system is working up to 35MeV in the ENEA laboratory at Frascati, Italy. For the Couple Cavity Linac ("CCL") modules, we are also confident since one of them has been successfully built and tested by the TERA Foundation and accelerated protons from 62 to 73MeV."

Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
In addition, there has been good progress in the creation of the Patient Positioning System ("PPS") which ensures that the patient is ideally prepared for the high accuracy and dose sparing proton treatments produced by the LIGHT system. The Diagnostic Quality CT scanner used in the treatment room to image patients in a seated position has been manufactured, and integration testing completed. A real time X-ray verification system which enables continuous imaging of moving tumours, has also been developed, a challenge in proton therapy. In addition, the robotic treatment chair which can move and rotate the patient with high precision has been successfully tested. Most significantly, the overall connectivity from the PPS and the LIGHT system accelerating units has been established and successfully evaluated with system function emulation tools.